bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
09 Aprile 2024 - 2:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive, accurate tests for the detection of early-stage cancer
and lung disease, today announced the expansion of its partnership
with the American Cancer Society (ACS) to raise funding for ACS’
Lung Quality Improvement (QI) initiative to increase the rate of
lung cancer screening. Learn more at the joint ACS/bioAffinity
donation page.
Initially launched in November 2023 to support local lung cancer
screening, bioAffinity Technologies and its ACS South Region
partner have expanded the geographic reach to include ACS Lung QI
sites across the country. The campaign highlights the value of
early screening and provides information about bioAffinity
Technologies’ CyPath® Lung, a noninvasive test to improve early
detection of lung cancer.
“There is no question that early detection of lung cancer is the
key to survival. Thanks to programs like the American Cancer
Society’s Lung QI and ‘Get Screened’ initiatives, more Americans
will be able to find lung cancer at an early stage when treatment
options are more effective,” bioAffinity President and Chief
Executive Officer Maria Zannes said. “We are proud to work with the
American Cancer Society, and we thank all our donors for their
generosity and commitment to saving lives.”
“Our lung cancer screening programs are focused on improving
survival rates for one of the deadliest cancers. Support from
corporate partners like bioAffinity helps us both raise awareness
about the importance of screening and provide tangible resources to
assist anyone at risk for lung cancer,” said Patrick Isenberg,
Director of Corporate Relations for ACS South Region. The ACS
website has an interactive map that helps people eligible for
screening find a cancer screening location near them.
About CyPath® Lung
CyPath® Lung uses advanced flow cytometry and artificial
intelligence (AI) to identify cell populations in patient sputum
that indicate malignancy. Automated data analysis helps determine
if cancer is present or if the patient is cancer-free. CyPath® Lung
incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl)
porphyrin (TCPP), that is preferentially taken up by cancer and
cancer-related cells. Clinical study results demonstrated that
CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy
in detecting lung cancer in patients at high risk for the disease
who had small lung nodules less than 20 millimeters. Diagnosing and
treating early-stage cancer can improve outcomes and increase
patient survival.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. For more information, visit
www.bioaffinitytech.com and follow us on LinkedIn, Facebook and
X.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding plans to increase lung cancer
screening and the effect of the expanded partnership with the ACS.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to increase lung cancer
screening to save lives and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, and its subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. While the Company believes these
forward-looking statements are reasonable, readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The information in this release is
provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409551485/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com Investor Relations
Dave Gentry RedChip Companies Inc. 1-800-RED-CHIP (733-2447) or
407-491-4498 BIAF@redchip.com
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Set 2023 a Set 2024